Effectiveness of shunt treatment for persons with idiopathic normal pressure hydrocephalus report was published by the Norwegian Institute of Public Health at the end of May of 2018

Jun 2018

On the 30th of May of 2018, Norwegian Institute of Public Health (NIPH) has published a report "Effectiveness of shunt treatment for persons with idiopathic normal pressure hydrocephalus: evidence base for a shared decision-making tool", which was earlier commissioned to NIPH by My treatment choices platform “Minebehandlingsvalg”. The main objective of the report was to find and summarize key findings from systematic reviews about the effects of shunts in the treatment of idiopathic normal pressure hydrocephalus.

As a result, three relevant systematic reviews were identified, however, there were no any controlled studies that compared treatment with shunts versus no treatment for idiopathic normal pressure hydrocephalus. Hence, it was impossible to determine the effectiveness of shunts.

The report in Norwegian can be seen here.

See full details in Norwegian in here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

Rapid HTAs of five medical devices released in Tuscany

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Belgian KCE developing procedure for assessment of digital health technologies

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Assessments of monitoring and diagnostics of atrial fibrillation products released in Sweden

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

HTAs published by FinCCHTA in February 2022

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Theme survey on products for monitoring and diagnostics of sepsis launched by Swedish TLV

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.